Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of “Hold” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given a consensus rating of “Hold” by the nineteen research firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $148.9412.

Several research firms have recently weighed in on ILMN. Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Barclays upped their price objective on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a report on Wednesday, June 24th. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $125.00 to $185.00 in a research note on Wednesday, June 10th. Canaccord Genuity Group reduced their target price on Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Finally, Guggenheim upped their price target on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, June 29th.

Illumina Price Performance

NASDAQ ILMN opened at $188.68 on Monday. Illumina has a 52 week low of $88.00 and a 52 week high of $189.46. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The business’s fifty day simple moving average is $154.74 and its 200-day simple moving average is $139.45. The firm has a market cap of $28.55 billion, a PE ratio of 34.31, a P/E/G ratio of 3.53 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the firm posted $0.97 earnings per share. Illumina’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts anticipate that Illumina will post 5.21 earnings per share for the current year.

Insider Activity at Illumina

In other Illumina news, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the sale, the chief accounting officer directly owned 14,946 shares in the company, valued at $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last quarter. 2.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ILMN. Capital World Investors grew its stake in shares of Illumina by 0.6% in the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after buying an additional 124,323 shares in the last quarter. State Street Corp raised its holdings in shares of Illumina by 3.2% in the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after buying an additional 190,324 shares during the period. WCM Investment Management LLC lifted its stake in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. AQR Capital Management LLC lifted its stake in Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after acquiring an additional 1,028,099 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after acquiring an additional 130,139 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.